Quick Answer
Estrella Immunopharma, Inc. reported Cash and Equivalents of $1.38 million for fiscal year 2025.
Estrella Immunopharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.38M | +51.0% |
| 2024 | $916.9K | -78.0% |
| 2024 | $4.17M | +68.0% |
| 2023 | $2.48M | +5976.0% |
| 2022 | $40.8K | -91.5% |
| 2021 | $478.9K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.63M | -9.5% | +23.5% |
| June 30, 2025 | $1.32M | -68.4% | +212.4% |
| March 31, 2025 | $421.5K | -91.1% | -54.0% |
| December 31, 2024 | $916.9K | -89.9% | -49.0% |
| September 30, 2024 | $1.80M | -91.9% | -56.8% |
| June 30, 2024 | $4.17M | +68.0% | -11.9% |
| March 31, 2024 | $4.73M | +15984.7% | -47.7% |
| December 31, 2023 | $9.05M | — | -59.1% |
- Estrella Immunopharma, Inc. showed an increase of +51.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Estrella Immunopharma, Inc.’s cash and equivalents has grown by 189.1% (from $478.9 thousand to $1.38 million).
- The most recent figure is from Estrella Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: